Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INNATE LACK OF SUSCEPTIBILITY OF UGANDAN TRYPANOSOMA-BRUCEI-RHODESIENSE TO DL-ALPHA-DIFLUOROMETHYLORNITHINE (DFMO)
Autore:
ITEN M; MATOVU E; BRUN R; KAMINSKY R;
Indirizzi:
SWISS TROP INST CH-4002 BASEL SWITZERLAND SWISS TROP INST CH-4002 BASEL SWITZERLAND LIVESTOCK HLTH RES INST TORORO UGANDA
Titolo Testata:
Tropical medicine and parasitology
fascicolo: 3, volume: 46, anno: 1995,
pagine: 190 - 194
SICI:
0177-2392(1995)46:3<190:ILOSOU>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
GAMBIENSE SLEEPING SICKNESS; CENTRAL ZAIRE; TRIAL; MELARSOPROL; RESISTANCE; NIFURTIMOX; INVITRO; KENYA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
M. Iten et al., "INNATE LACK OF SUSCEPTIBILITY OF UGANDAN TRYPANOSOMA-BRUCEI-RHODESIENSE TO DL-ALPHA-DIFLUOROMETHYLORNITHINE (DFMO)", Tropical medicine and parasitology, 46(3), 1995, pp. 190-194

Abstract

Trypanosoma brucei rhodesiense isolates from South East Uganda were characterized for susceptibility to the drugs suramin, nifurtimox, melarsoprol and DL-alpha-difluoromethylornithine (DFMO). Two different assays were used to determine the drug susceptibility of the field isolates: the [H-3]hypoxanthine incorporation assay (24 hours) and the long term viability assay (10 days). All trypanosome stocks were susceptible to suramin and nifurtimox. Differences in the susceptibility to melarsoprol were observed in the [H-3]hypoxanthine incorporation assay, but could not be confirmed in the long term viability assay. All T. b. rhodesiense stocks were found in vitro to have innate tolerance to DFMO, under conditions where T. b. gambiense stocks from West Africa were susceptible to the drug. Ugandan T. b. rhodesiense stocks did respond to 25-100 mu g/ml after 10 days of drug exposure, but the DFMO level reached in cerebrospinal fluid during treatment is only 16.3 +/- 7.8 mug/ml. Therefore, DFMO is not an appropriate alternative or backup drug for treatment of Rhodesian sleeping sickness in Uganda.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/21 alle ore 02:51:33